A study of 273 Caucasian patients with RA treated with MTX for at least 6 months showed that there were no associations between TYMS gene polymorphisms and the toxicity of MTX treatment (Swierkot et al., 2015). The gene discussed is TYMS; the disease is rheumatoid arthritis.